Top 20 big pharma saw 3.4% market cap decline in Q1

The world’s top 20 biopharma companies reported a drop in their combined market capitalization by 3.4% from $3.61 trillion at the end of 2022, to $3.49 trillion after the first three months of 2023.

GlobalData, the data and analytics company, has crunched the numbers and analyzed the findings, which it attributes to the challenging current macroeconomic environment of high inflation and increasing capital costs.

A decrease in market capitalization was indicated for 12 of the top 20 players from the end of one quarter to the next, GlobalData found. The other eight did experience growth, with Germany’s Bayer (BAYN: DE) reporting the healthiest rise at more than 23%, followed by Danish drugmaker Novo Nordisk (NOV: N), which saw an 18% jump.